Donanemab Bests Aducanumab in Head-to-Head AD Trial ...Middle East

Patients with early, symptomatic Alzheimer's disease had significantly better amyloid clearance and plaque reduction after 6 months of treatment with donanemab compared with aducanumab. Medscape Medical News

Hence then, the article about donanemab bests aducanumab in head to head ad trial was published today ( Friday 28/04/2023 - 12:16 AM ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Donanemab Bests Aducanumab in Head-to-Head AD Trial )

Also on site :

• Hollywood mourns loss of beloved makeup artist Jasen Kaplan
• Rose Parade Viewers 'Floored' by 'Disaster' Finale Performance: 'Yikes'
• Taylor Swift attends Este Haim’s NYE wedding to Jonathan Levin at boutique hotel in California